mercredi 7 août 2019

Onco Actu du 7 août 2019


UCLA study links progenitor cells to age-related prostate growth [UCLA]
The prostates of older mice contain more luminal progenitor cells — cells capable of generating new prostate tissue — than the prostates of younger mice, UCLA researchers have discovered. 


Bone in a dish’ opens new window on cancer initiation, metastasis, bone healing [OHSU]
Like real bone, the material developed at OHSU has a 3D mineral structure populated with living cells, providing a unique model to study bone function, diseases, regeneration.

  DEP., DIAG. & PRONO.  

These Medical Devices Are Inserted Into 500,000 Patients Each Year — but Are Tough to Sterilize [NY Times]
Duodenoscopes have sickened hundreds of patients in hospital outbreaks. Now some experts are demanding the devices be redesigned or taken off the market. 

Final Recommendation Statement - Pancreatic Cancer: Screening [USPSTF]
The USPSTF recommends against screening for pancreatic cancer in asymptomatic adults.


Common prostate cancer treatment may increase risk of fatal heart condition [AHA]
Kovacs suggested that oncologists and cardiologist work together to manage QT prolongation and the risk of torsade de pointes in high-risk prostate cancer patients.


Amid rising concern, pay-to-play clinical trials are drawing federal scrutiny [STAT]
Experts say these trials are ethically fraught for a number of reasons: At worst, they run the risk of being a guise for an enterprise looking to profit from desperate patients. But even when intentions are sound, the trials are likely to only enroll those patients who can afford to participate, thereby skewing the results.


FDA Approvals Provide Advances for a Range of Cancer Types [Cancer Research Catalyst]
Molecularly targeted therapeutics are the cornerstone of precision oncology. So, this flurry of approvals highlights that progress in this important area of cancer care is continuing unabated.


In draft guidance, NICE fails to back Clovis's PARP inhibitor Rubraca [EndPoints]
In its draft guidance, NICE suggested that while Rubraca extends the time until cancer progresses compared with routine care — the magnitude of this benefit is uncertain because mature trial data are not available yet.

NICE recommends additional treatment option for people with early breast cancer [NICE]
Neratinib (also called Nerlynx and marketed by Pierre Fabre) is recommended, under the terms of a commercial arrangement, for people with this type of breast cancer who are less than 1 year from completing trastuzumab (Herceptin)-based treatment following surgery (called adjuvant treatment).


AstraZeneca's Lynparza helps prostate cancer patients live longer: study [Reuters]
Lynparza, which is being jointly developed with Merck, is already approved for advanced ovarian cancer and metastatic breast cancer. The drug is an important growth driver for the British drugmaker as it builds its cancer treatment portfolio.

Lynparza Phase III PROfound trial in HRR* mutation-selected metastatic castration-resistant prostate cancer met primary endpoint [AstraZeneca]
Only PARP inhibitor with positive Phase III results in four different cancer types (ovarian, breast, pancreatic and prostate).


ADC Therapeutics and SOPHiA GENETICS Partner for Biomarker Discovery in Pivotal Phase II Clinical Trial [SOPHiA GENETICS]
Study to identify genomic markers associated with clinical response to ADCT-402 (loncastuximab tesirine) inrelapsed or refractory diffuse large B-cell lymphoma (DLBCL).


Tessa Richards: My view, and that of 3980 other patients [BMJ]
All.Can is an international initiative, which seeks to “identify ways to optimise use of resources in cancer care to improve patient outcomes.” Its survey was designed by Quality Health and conducted across 10 countries: the US, UK, Australia, Canada, Belgium, Poland, Italy, Sweden, France, and Spain.